Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 September 2015
Start of review of nasal and mouth sprays containing fusafungine
The Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of nasal and mouth sprays containing the antibiotic fusafungine, used to treat infections of the upper airways. The PRAC aims to review the available data on the benefits and risks of these medicines and issue an opinion on their marketing authorisations across the European Union.
More information is included in the table below.
|Agenda - PRAC draft agenda of meeting 7-10 September 2015|
Start of referral procedure
|Fusafungine containing medicinal products for oromucosal and nasal use|